What question did this study set out to answer?

This research aims to evaluate the effects of GLP-1RA and GLP-1/GIPRA on glycemic control and weight in youth with type 1 diabetes, and identify characteristics of nonresponders.

June 7, 2026

2100-P: Glucagon-Like Peptide 1 Receptor Agonist (GLP-1RA) or GLP-1RA/Glucose-Dependent Insulinotropic Polypeptide RA (GLP-1/GIPRA) Effects in Youth/Young Adults (Y/YA) with Type 1 Diabetes and Characteristics of Nonresponders

Key Points

This research aims to evaluate the effects of GLP-1RA and GLP-1/GIPRA on glycemic control and weight in youth with type 1 diabetes, and identify characteristics of nonresponders.
Review of Y/YA with T1D treated with GLP-1RA or GLP-1/GIPRA.
Data collected on demographics, BMI, A1c, insulin dosing, and adverse events over 18 months.
Statistical analysis using Student’s t-test and chi-square tests.
GLP-1RA or GLP-1/GIPRA treatment led to significant improvements in glycemia and weight along with reduced insulin dosage (p<0.05).
32% of participants were non-responders, with non-response linked to obesity onset prior to puberty (p=0.0275) and limited to a single form of GLP-1RA or GLP-1/GIPRA (p=0.004).

Abstract

Introduction and Objective: Early data suggest that GLP-1-RA and GLP-1/GIPRA improve A1c and weight in adults with type 1 diabetes (T1D), but data in Y/YA with T1D are more limited and features of those that do not respond are not explored. Methods: We performed a review of Y/YA with T1D who took a GLP-1RA or GLP-1/GIPRA. Demographics, BMI, timing of overweight or obesity (OO) onset, glycemia (A1c, continuous glucose monitoring), insulin dosing and gastrointestinal adverse events from date of initial GLP-1RA or GLP-1/GIPRA prescription up to 18 months of treatment were extracted. A responder was defined as ≥5% weight loss and/or ≥0.4% HbA1c decrease. Student’s t-test and chi-square tests were used for group comparison. Results: Forty-eight Y/YA were included (mean age 18.6±2.7 y, T1D duration 8.3±4.9 y, A1c 8.0±1.5%, 72.9% female, Table). GLP-1RA or GLP-1/GIPRA use led to glycemic and weight improvements and decreased insulin dosage from baseline (p0.05). Non-response was seen in 32% and correlated with OO onset prior to puberty (p=0.0275) and only a single GLP-1RA or GLP-1/GIPRA form trialed (p=0.004). Conclusion: GLP1-RA and GLP-1/GIPRA show promise in Y/YA and warrant a prospective trial. Additional research in T1D is needed regarding ideal dosing and identification of subsets of people most likely to benefit. Disclosure L.A. Waterman: None. K.J. Nadeau: None. H.K. Akturk: Consultant; Current; Roche, Medtronic, Dexcom, Inc. Research Support; Current; Roche, Abbott. S. Polsky: Research Support; Current; Leona M. and Harry B. Helmsley Charitable Trust, National Institute of Diabetes and Digestive and Kidney Diseases, JDRF, University of Colorado. Other - honoraria for speaking engagements; Current; Children's Diabetes Foundation. Other - honororia for speaking engagements; Current; American Diabetes Association. Board Member; Current; American College of Diabetology. Other - unpaid work to write articles for online publication; Ended; diaTribe. Research Support; Ended; Dexcom, Inc. Other - travel and lodging expenses paid for a meeting; Ended; Insulet Corporation. Other - honororia for speaking engagements; Current; AACE. A.J. Karami: None. E. Cobry: None.

Mark Helpful

Bookmark

Relay